Johnson & Johnson has announced a significant $5.5 billion settlement aimed at resolving tens of thousands of lawsuits alleging its talc-based baby powder and other talc products caused ovarian cancer. This landmark agreement, confirmed on July 27, marks a pivotal moment in a protracted legal battle that has spanned a decade and could bring closure to the company’s extensive talc litigation.
The settlement encompasses approximately 76,000 claims, including those consolidated in federal court in New Jersey and related state court cases, effectively addressing nearly all outstanding talc claims. This follows previous settlements by J&J that resolved the majority of cases alleging asbestos contamination in its talc products led to mesothelioma. Plaintiffs’ legal representatives have acknowledged the deal as a favourable resolution after years of litigation. The agreement’s finalisation is contingent upon acceptance by 95% of the ovarian cancer claimants in either state or federal court.
Erik Haas, J&J’s vice president of litigation, characterised the claims as “meritless” and stated the company’s willingness to settle to achieve closure. He expressed confidence in J&J’s ability to prevail in further litigation, citing a strong track record in tried cases. “This resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas remarked. J&J anticipates paying $3 billion in 2027, with further payments scheduled for 2028. The total payout could potentially exceed $7 billion, depending on claimant participation, as the settlement assigns specific values to qualifying ovarian cancer claims without capping J&J’s total expenditure, according to Chris Seeger, an attorney involved in the negotiations.
This settlement arrives after a series of courtroom victories for Johnson & Johnson. These include successful individual trials, strategic disqualification of plaintiffs’ counsel, and favourable rulings against expert witnesses presented by the plaintiffs. Notably, a federal judge recently cast doubt on the ability of individual plaintiffs to definitively prove that talc specifically caused their ovarian cancer, a significant legal development. J&J has consistently maintained that its talc products are safe and asbestos-free, ceasing sales of talc-based baby powder in the U.S. in 2020 in favour of a cornstarch alternative.
The litigation had previously been stalled for over three years as J&J pursued, unsuccessfully, a “Texas two-step” strategy involving three bankruptcy filings through a shell subsidiary, all of which were dismissed. Prior to these bankruptcy attempts, J&J had a mixed record in talc trials, including a multi-billion dollar verdict in favour of 22 women who alleged baby powder caused their ovarian cancer, though some verdicts were later reduced on appeal. Unlike the proposed bankruptcy settlements, the current agreement exclusively addresses existing claims and does not cover future lawsuits. This focus on current claims, according to Seeger, allows for greater financial allocation to existing plaintiffs and accelerates payment timelines, with all claims expected to be settled within 18 months, a significant departure from the decade-plus payment schedules previously considered.
... J&J Agrees $5.5 Billion Settlement to Resolve Decades of Talc Lawsuits ... Naijaonpoint.